Difference between revisions of "Allopurinol (Zyloprim)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Xanthine oxidase inhibitor. <br>Route: PO/IV <br>Extravasation: unknown For conciseness and simplicity, HemOnc.org currently will foc...") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: unknown | <br>Extravasation: unknown | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
''No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.'' | ''No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.'' | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1966-08-19: Initial approval | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway | ||
| + | |||
| + | ==References== | ||
| + | *'''FLORENCE:''' Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. [https://doi.org/10.1093/annonc/mdv317 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26216382/ PubMed] [https://clinicaltrials.gov/study/NCT01724528 NCT01724528] | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Xanthine oxidase inhibitors]] | ||
| + | |||
| + | [[Category:FDA approved in 1966]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:07, 29 June 2024
General information
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
History of changes in FDA indication
- 1966-08-19: Initial approval
Also known as
- Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway
References
- FLORENCE: Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. link to original article PubMed NCT01724528